235 related articles for article (PubMed ID: 36806724)
1. Awareness and attitudes of oncology specialists toward dihydropyrimidine dehydrogenase testing in Saudi Arabia.
Sukkarieh HH; AlSagoor T; Alnuhait M; Bustami R; Bryson S; Adem FMK; Abdalla H; Karbani G
Cancer Rep (Hoboken); 2023 Feb; 6(2):e1704. PubMed ID: 36806724
[TBL] [Abstract][Full Text] [Related]
2. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
3. [Dihydropyrimidine dehydrogenase deficiency screening for management of patients receiving a fluoropyrimidine: Results of two national practice surveys addressed to clinicians and biologists].
Loriot MA; Masskouri F; Carni P; Le Malicot K; Seitz JF; Michel P; Legoux JL; Bouché O; André T; Faroux R; Delaloge S; Malka D; Guigay J; Thariat J; Thomas F; Barin-Le-Guellec C; Ciccolini J; Boyer JC; Étienne-Grimaldi MC
Bull Cancer; 2019 Sep; 106(9):759-775. PubMed ID: 31253356
[TBL] [Abstract][Full Text] [Related]
4. Current diagnostic and clinical issues of screening for dihydropyrimidine dehydrogenase deficiency.
Etienne-Grimaldi MC; Pallet N; Boige V; Ciccolini J; Chouchana L; Barin-Le Guellec C; Zaanan A; Narjoz C; Taieb J; Thomas F; Loriot MA;
Eur J Cancer; 2023 Mar; 181():3-17. PubMed ID: 36621118
[TBL] [Abstract][Full Text] [Related]
5. Dihydropyrimidine Dehydrogenase Deficiency and Implementation of Upfront DPYD Genotyping.
White C; Scott RJ; Paul C; Ziolkowski A; Mossman D; Fox SB; Michael M; Ackland S
Clin Pharmacol Ther; 2022 Oct; 112(4):791-802. PubMed ID: 35607723
[TBL] [Abstract][Full Text] [Related]
6. Capecitabine-based treatment of a patient with a novel DPYD genotype and complete dihydropyrimidine dehydrogenase deficiency.
Henricks LM; Siemerink EJM; Rosing H; Meijer J; Goorden SMI; Polstra AM; Zoetekouw L; Cats A; Schellens JHM; van Kuilenburg ABP
Int J Cancer; 2018 Jan; 142(2):424-430. PubMed ID: 28929491
[TBL] [Abstract][Full Text] [Related]
7.
Lešnjaković L; Ganoci L; Bilić I; Šimičević L; Mucalo I; Pleština S; Božina N
Pharmacogenomics; 2023 Jan; 24(2):93-106. PubMed ID: 36636997
[TBL] [Abstract][Full Text] [Related]
8. Treating patients with dihydropyrimidine dehydrogenase (DPD) deficiency with fluoropyrimidine chemotherapy since the onset of routine prospective testing-The experience of a large oncology center in the United Kingdom.
Wang L; Howlett S; Essapen S
Semin Oncol; 2022 Apr; 49(2):170-177. PubMed ID: 35027218
[TBL] [Abstract][Full Text] [Related]
9. Patients homozygous for DPYD c.1129-5923C>G/haplotype B3 have partial DPD deficiency and require a dose reduction when treated with fluoropyrimidines.
Meulendijks D; Henricks LM; van Kuilenburg AB; Jacobs BA; Aliev A; Rozeman L; Meijer J; Beijnen JH; de Graaf H; Cats A; Schellens JH
Cancer Chemother Pharmacol; 2016 Oct; 78(4):875-80. PubMed ID: 27544765
[TBL] [Abstract][Full Text] [Related]
10. Joint Belgian recommendation on screening for DPD-deficiency in patients treated with 5-FU, capecitabine (and tegafur).
Casneuf V; Borbath I; Van den Eynde M; Verheezen Y; Demey W; Verstraete AG; Bm Claes K; Haufroid V; Geboes KP
Acta Clin Belg; 2022 Apr; 77(2):346-352. PubMed ID: 33423619
[TBL] [Abstract][Full Text] [Related]
11. Survey of US Medical Oncologists' Practices and Beliefs Regarding
Koo K; Pasternak AL; Henry NL; Sahai V; Hertz DL
JCO Oncol Pract; 2022 Jun; 18(6):e958-e965. PubMed ID: 35239419
[TBL] [Abstract][Full Text] [Related]
12. Severe fluoropyrimidine toxicity due to novel and rare DPYD missense mutations, deletion and genomic amplification affecting DPD activity and mRNA splicing.
van Kuilenburg AB; Meijer J; Maurer D; Dobritzsch D; Meinsma R; Los M; Knegt LC; Zoetekouw L; Jansen RL; Dezentjé V; van Huis-Tanja LH; van Kampen RJ; Hertz JM; Hennekam RC
Biochim Biophys Acta Mol Basis Dis; 2017 Mar; 1863(3):721-730. PubMed ID: 28024938
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of predictive tests for screening for dihydropyrimidine dehydrogenase deficiency.
van Staveren MC; Guchelaar HJ; van Kuilenburg AB; Gelderblom H; Maring JG
Pharmacogenomics J; 2013 Oct; 13(5):389-95. PubMed ID: 23856855
[TBL] [Abstract][Full Text] [Related]
14. Complete DPYD genotyping combined with dihydropyrimidine dehydrogenase phenotyping to prevent fluoropyrimidine toxicity: A retrospective study.
De Metz C; Hennart B; Aymes E; Cren PY; Martignène N; Penel N; Barthoulot M; Carnot A
Cancer Med; 2024 Mar; 13(6):e7066. PubMed ID: 38523525
[TBL] [Abstract][Full Text] [Related]
15. Implementation and clinical benefit of DPYD genotyping in a Danish cancer population.
Paulsen NH; Pfeiffer P; Ewertz M; Fruekilde PBN; Feddersen S; Holm HS; Bergmann TK; Qvortrup C; Damkier P
ESMO Open; 2023 Feb; 8(1):100782. PubMed ID: 36791638
[TBL] [Abstract][Full Text] [Related]
16. Dutch Pharmacogenetics Working Group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines.
Lunenburg CATC; van der Wouden CH; Nijenhuis M; Crommentuijn-van Rhenen MH; de Boer-Veger NJ; Buunk AM; Houwink EJF; Mulder H; Rongen GA; van Schaik RHN; van der Weide J; Wilffert B; Deneer VHM; Swen JJ; Guchelaar HJ
Eur J Hum Genet; 2020 Apr; 28(4):508-517. PubMed ID: 31745289
[TBL] [Abstract][Full Text] [Related]
17. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing.
Caudle KE; Thorn CF; Klein TE; Swen JJ; McLeod HL; Diasio RB; Schwab M
Clin Pharmacol Ther; 2013 Dec; 94(6):640-5. PubMed ID: 23988873
[TBL] [Abstract][Full Text] [Related]
18. The Prevalence of DPYD*9A(c.85T>C) Genotype and the Genotype-Phenotype Correlation in Patients with Gastrointestinal Malignancies Treated With Fluoropyrimidines: Updated Analysis.
Maharjan AS; McMillin GA; Patel GK; Awan S; Taylor WR; Pai S; Frankel AE; Nelson C; Wang B; Hosein PJ; Singh AP; Khushman M
Clin Colorectal Cancer; 2019 Sep; 18(3):e280-e286. PubMed ID: 31160238
[TBL] [Abstract][Full Text] [Related]
19. Implementation of dihydropyrimidine dehydrogenase deficiency testing in Europe.
de With M; Sadlon A; Cecchin E; Haufroid V; Thomas F; Joerger M; van Schaik RHN; Mathijssen RHJ; Largiadèr CR;
ESMO Open; 2023 Apr; 8(2):101197. PubMed ID: 36989883
[TBL] [Abstract][Full Text] [Related]
20. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
Ostapowicz A; Dołegowska B
Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
